Project 2: Nonmyeloablative Hematopoietic Cell Allotransplants This project investigates allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning to treat patients with advanced hematological malignancies who are elderly and/or have cormobidities precluding high-dose HCT. Conditioning involves fludarabine (FLU) and 2 Gy total body irradiation (TBI), which lack serious toxicities. Post-grafting immunosuppresssion with mycophenolate motetil and a calcineurin inhibitor both aids engraftment and controls graft-vs.-host disease (GVHD). Graft-vs-tumor (GVT) effects are used to eradicate cancer. Avoiding toxicities has enabled us to surmount age and comorbidity limitations associated with myeloablative regimens. For these reasons and given that median ages of patients at diagnoses of most candidate diseases range from 65-70 years, the number of patients treatable by allogeneic HCT has greatly increased. To date, >1,600 patients have been enrolled on our nonmyeloablative protocols. This project will focus on relapse and acute GVHD.
Specific Aim 1 consists of phase l/ll disease-specific protocols aimed at reducing relapse for patients with chronic lymphocytic lymphoma, acute myelocytic leukemia, and Hodgkin lymphoma. Seventy percent of patients who relapse do so Within the first year. We hypothesize that early relapse is due to blunting of GVT effects by early posttransplant immune compromise. Later, the immune system recovers as immunosuppressive drugs are being tapered or discontinued, thereby allowing powerful GVT effects to develop. The protocols intend to control tumor burden with specific drugs or an antibody-drug conjugate given after HCT, thereby bridging the early, immunocompromised post-transplant period without relapse until immune function recovers and GVT effects occur.
Specific Aim 2 focuses on reducing acute GVHD.
Aim 2 a will use donor statin treatment to prevent acute GVHD among HLA-matched related recipients.
Aim 2 b is based on a just concluded, 3-arm, randomized, phase 11 study involving 208 HLA-matched unrelated recipients, which showed a significant reduction in acute GVHD with added sirolimus;Protocol 2448 is a phase 111 study comparing MMF/CSP/sirolimus to MMF/CSP.
Aim 2 c, HLA-mismatched grafts, will investigate the addition of sirolimus to MMF/CSP. Project 2 is a close collaboration with Project 1 to explore to what extent HLA typing can be refined, thereby extending donor options. A unique aspect of this project is that most of the proposed trials are conducted within a consortium that includes 23 academic centers outside of Seattle.
We have developed a nonmyeloablative regimen for allogeneic HCT to treat patients with advanced, otherwise fatal hematologic cancer who are older or have comorbid conditions. The regimen relies on graft vs. tumor effects to cure cancer. This has enabled treating a previously un-served group of individuals who constitute a majority of patients diagnosed with hematologic malignancies. Initial results among >1,600 patients have been very encouraging. Here, we propose to further improve outcomes by designing disease specific protocols focused on reducing relapse while other protocols are aimed at better GVHD control.
|McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807|
|Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193|
|Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515|
|Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334|
|Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849|
|Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276|
|Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163|
|Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629|
|Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562|
|Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313|
Showing the most recent 10 out of 1845 publications